Early Insights Show Varied Pharmacogenetics of Medicinal Cannabis in the Caribbean Population скачать в хорошем качестве

Early Insights Show Varied Pharmacogenetics of Medicinal Cannabis in the Caribbean Population

Tags: Medical Cannabis, Personalized Medicine, Pharmacogenetics, Metabolism, Product Efficacy, Cannabis Efficacy & Safety Carika Weldon, Founder and CEO, CariGenetics Limited (‪@CariGeneticsltd‬) presents, “Early Insights Show Varied Pharmacogenetics of Medicinal Cannabis in the Caribbean Population” at CannMed 2025. The Caribbean is poised to become the first intensive zone of medicinal cannabis legalization in the world. However, the genetics and pharmacogenetics of this diverse population have not been well studied in relation to cannabis use, which has significant implications for dosing and successful medical application. Individual responses to cannabis-based therapies can vary greatly due to genetic differences in metabolism, underscoring the need for region-specific research. As part of the Caribbean Genome Programme delivered by CariGenetics, we have collected genetic data from individuals across several Caribbean islands over diverse ethnicities, assessing key genes involved in THC and CBD metabolism, as well as terpenes with energizing or relaxing effects. Our findings indicate a high prevalence (＞80%) of rapid metabolizers of CBD and THC among Afro-Caribbean individuals, with a clear pattern of a 1:1 CBD/THC ratio recommended for use, suggesting that standard dosing regimens may not be optimal for this population. This contrasts with 0% of Caucasian-Caribbean having rapid metabolism and needing up to 20:1 CBD/THC ratio. This trend also extends into the metabolism of minor cannabinoids. This has significant implications for medicinal cannabis use, as rapid metabolism may lead to reduced therapeutic effects at conventional doses, necessitating population-specific dosage recommendations and product formulations. Genetic patterns related to pain management, sleep, cannabis dependence, psychosis trigger from cannabis, and stress have also been assessed. Beyond immediate clinical applications, this research highlights the broader potential of pharmacogenetics in optimizing drug efficacy and safety for diverse populations. The Caribbean Genome Programme aims to sequence 100,000 genomes over three years, uncovering additional insights relevant to disease risk, diagnostics, and drug development. Our work underscores the importance of incorporating genetic diversity into precision medicine initiatives to improve therapeutic outcomes and ensure equitable access to optimized treatments. These findings set the stage for the development of population-specific medicinal cannabis formulations and personalized dosing strategies, ultimately advancing precision medicine for Caribbean populations and beyond. 0:00 - Intro 0:30 - The Need for Diverse Clinical Data 1:12 - The Caribbean: A Genetic Melting Pot 1:54 - The Population of the Caribbean 2:42 - What is CariGenetics? 3:22 - Medicinal Cannabis in the Caribbean 4:39 - One Size Does Not Fit All: Precision Medicine 5:02 - The Caribbean Genome Program 5:47 - Health and Wellness Tests 7:01 - Preliminary Study Data & Demographics 7:56 - THC and CBD Metabolism: Key Genes 8:15 - Surprising THC Metabolism Findings 9:23 - Surprising CBD Metabolism Findings 9:55 - CBD to THC Ratio and Terpenes 11:00 - Pain Management and Genetic Data 12:10 - Sleep Patterns and Cannabis Dependence 13:59 - Stress, Anxiety, and Psychosis Risk 14:40 - Key Takeaways from the Study 15:35 - The Future of CariGenetics 16:23 - Expanding Beyond Cannabis to Psychedelics 17:24 - Partnering for Personalized Medicine 17:37 - Free Tests and Conclusion Learn More about CannMed: https://cannmedevents.com/ Sign Up for Our Newsletter: https://share.hsforms.com/1oi57oJDnRN... The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.